

Disclosure on Securities Lending, Repo and Reverse Repo Transactions

ChinaAMC Hang Seng Hong Kong Biotech Index ETF

For the year ended 31 December 2023



Summary

As a tool for return enhancement, ChinaAMC Hang Seng Biotech ETF (the "Sub-Fund") has entered into securities lending transactions while adhering to its maximum level of up to 50% of the Sub-Fund's net asset value ("NAV"). As of 29 December 2023, the Sub-Fund's securities lending position totaled \$ 7,485,013, representing 9.37% of the NAV. Detailed data are presented in the following sections.

Part I - Global Data

(a) The amount of securities on loan as proportion of the fund's assets under	9.37%
management	
(b) The absolute amount of assets engaged in securities lending	7,485,013
(c) The absolute amount of the repo book	N/A
(d) The absolute amount of the reverse repo book	N/A

Part II - Concentration Data

(a) Top counterparties of securities lending transactions

Name of Counterparty	Amount (US dollar)
GOLDMAN SACHS INTERNATIONAL	3,623,703
BNP PARIBAS ARBITRAGE LONDON/PARIS	1,753,150
THE HONG KONG & SHANGHAI BANKING	1,145,924
CORPORATION LTD	
NATIXIS	962,235

Part III - Aggregate Transaction Data

(a) Securities financing transactions and securities borrowing transactions (in aggregate)

Term	Amount (US dollar)
Open	7,485,013



Currency	Amount (US dollar)
HKD	7,485,013

Geography	Amount (US dollar)
China - Hong Kong	1,145,924
USA	3,623,703
Europe Union	2,715,385

Settlement and Clearing	Amount (US dollar)
Bilateral	7,485,013

(b) Collateral (in aggregate)

Туре	Amount (US dollar)
Cash, Cash-equivalent & Money Market Instrument	1,204,794
Government Debt - Investment Grade	6,852,019

Currency	Amount (US dollar)
EUR	3,997,244
JPY	4,059,568

Tenor	Amount (US dollar)
Open	8,056,813

Part IV – Re-use and Re-hypothecation of Data

a) Share of collateral received that is re-used or re-hypothecated, compared to the maximum authorized amount of any

No reinvestment



b) Information on any restrictions on type of collateral received

For any non-cash collaterals, such as equity securities and fixed income securities, which may be received as collaterals in respect of the securities lending transactions, the Sub-Fund may hold not more than 30% of its NAV in securities which are not constituents of the Index.

Eligible collateral include cash, cash equivalents, government bonds, supranational bonds, corporate bonds, stocks, funds and money market instruments.

Collateral generally should not include (i) structured products whose payouts rely on embedded FDIs or synthetic instruments; (ii) securities issued by special purpose vehicles, special investment vehicles or similar entities; (iii) securitised products; or (iv) unlisted collective investment schemes.

Part V - Return Data

Туре	Amount (US dollar)
Revenue - To fund	15,448
Revenue - To other parties	6,621
Direct and Indirect Expense - To fund	
Direct and Indirect Expense - To other parties	

Part VI - Custodians

Name of Custodian	Amount of Collateral Assets Held
JP Morgan Luxembourg S.A	4,060,634
Bank of New York Mellon	3,996,179

Part VII - Collateral in Other Accounts

The proportion of collateral posted by funds which are held in segregated accounts, pooled accounts, or in any other accounts.

Туре	Proportion (in %) of collateral posted by the fund
Segregated accounts	100.00%
Pooled accounts	
Other accounts	